Vivek Subbiah: So much enthusiasm for delivering Precision Medicine every where.
Vivek Subbiah, made the following post on LinkedIn:
“Delighted to visit Park City, Utah to deliver a lecture on “Tissue Agnostic Precision Medicine” at the SUMO- Society of Utah Medical Oncologists.
Thankful to my dear friend, colleague & President- Elect of Society of Utah Medical Oncologists Dr. Mark Lewis for the invite.
Thrilled to meet with
- American Society of Clinical Oncology (ASCO) President Elect Dr. Robin Zon – such an amazing person.
- My amazing friend & GU Practice Changer Neeraj Agarwal, MD, FASCO.
- AI in Oncology star Arturo Loaiza-Bonilla MD.
So much enthusiasm for delivering Precision Medicine every where.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
Source: Vivek Subbiah/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023